-
New Zealand Football withdraws support for Infantino, urges review
-
UK vote count under way in Farage, Binface showdown
-
Hopes fade in Colombia as window to find quake survivors shuts
-
US, Mexico conduct security exercises near border
-
Trump announces tariffs of up to 100% on imported drones
-
Swiatek rolls past Rybakina for WTA Toronto title
-
Spieth among five sharing Memphis lead as PGA playoffs open
-
Vance says low oil prices are top US goal in Iran conflict
-
Boats rescue tourists as forest fire flames threaten Greek beaches
-
Hunt bags Euro sprint double, Ceh keeps discus title
-
Good vibes powering Djokovic return to Cincinnati
-
'Dream come true': Owners reunite with pets in quake-hit Colombia
-
Britain's Hunt wins 200m for European sprint double
-
US stocks gain after benign inflation data, oil prices retreat
-
Draper dumped as Norrie saves face for Britain in Cincinnati
-
LeBron's Sixers in spotlight as full 2026-27 NBA schedule revealed
-
England opener Gay out for duck in Pakistan warm-up
-
Kennedy Center board votes to restore Trump name: reports
-
Europe swelters under fresh wave of extreme heat
-
Barcelona agree to sell Torres to PSG: media
-
French Olympic gold medallist Florent Manaudou announces retirement
-
Romania shuts nuclear plant as Danube drops
-
Tourists rescued by boat as forest fire threatens Greek beaches
-
Millions of Europeans struggle with another wave of extreme heat
-
Indicted Raul Castro reappears after months out of public view
-
Israel reopens once-closed West Bank settlement
-
Italian teen Curtis breaks women's 50m backstroke world record for second time
-
Taylor to captain New Zealand for first time against Bulls
-
Taulagi steps out of 'comfort zone' with code switch to French Top 14 new boys
-
Carrick urges Man Utd to push for more signings to boost title bid
-
Leicester's Thai owners put troubled club up for sale: reports
-
'This was my World Cup' says Somali ref after UEFA Super Cup
-
Stocks steady as US inflation worries ease, oil slips
-
Survivors tell of horror of Zimbabwe ferry sinking as death toll hits 46
-
Porsche to end production of flagship electric car: report
-
Juventus forward Vlahovic signs three-year Besiktas deal
-
Twitch sparks gamers' wrath with Amazon AI sharing deal
-
Tielemans apologises for offending Villa fans with Man Utd boast
-
Blaze forces families to abandon Turkish tour boat
-
Stocks gain as US inflation worries ease, oil slips
-
'If you can, move!' say Rome's viral dancing seniors
-
Heavy rain soaks eastern Japan, prompting highest-level warning
-
Zambia voters weigh Hichilema's economic record
-
Celtic boss O'Neill 'much better' after hospital procedure
-
SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026
-
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
-
Hodgkinson sets up Werro showdown after Euro 800m drama
-
Maghreb sees demographic shift with fertility at historic low
-
'How many will die?': the mysterious ailment killing Kenyan elephants
-
European stocks gain as oil prices ease
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
E.AbuRizq--SF-PST